.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,142,811

« Back to Dashboard

Details for Patent: 8,142,811

Title:Controlled release hydrocodone formulations
Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.
Inventor(s): Oshlack; Benjamin (New York, NY), Huang; Hua-Pin (Englewood Cliffs, NJ), Masselink; John K. (Old Tappan, NJ), Tonelli; Alfred P. (Congers, NY)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Filing Date:Feb 17, 2009
Application Number:12/378,586
Claims:1. A solid oral controlled-release dosage form comprising a compressed granulation in the form of a controlled release matrix, the compressed granulation comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, a controlled release material comprising a methacrylic acid polymer or copolymer, and optionally a therapeutically effective amount of a non-opioid drug; wherein the hydrocodone and the optional non-opioid drug are the only active agents in the dosage form, and the dosage form provides an in-vitro release rate of the hydrocodone or salt thereof when measured b the USP Basket Method at 100 rpm in 700 ml Simulated Gastric Fluid (SGF) at 37.degree. C. for 1 hour and thereafter switching to 900 ml with Phosphate Buffer to a pH of 7.5 at 37.degree. C., such that at least 20% by weight hydrocodone or salt thereof is released at 4 hours, from about 20% to about 65% by weight hydrocodone or salt thereof is released at 8 hours, from about 45% to about 85% by weight hydrocodone or salt thereof is released at 12 hours, and at least 80% by weight hydrocodone or salt thereof is released at 24 hours, and after a first administration to a human patient, provides a C.sub.24/C.sub.max hydrocodone ratio of 0.55 to about 0.85, and a therapeutic effect for at least about 24 hours.

2. The dosage form of claim 1, wherein the dosage form provides a rate of absorption of hydrocodone during the time period from T.sub.max to about 24 hours after oral administration of the dosage form which is from about 45% to about 85% of the rate of elimination of hydrocodone during the same time period.

3. A process for the preparation of the solid oral controlled-release dosage form of claim 1, the process comprising a step of combining the hydrocodone or the pharmaceutically acceptable salt thereof and the controlled release material to form the compressed granulation in the form of the matrix.

4. The dosage form of claim 1, wherein the compressed granulation comprises the hydrocodone, the non-opioid drug and the controlled release material.

5. The dosage form of claim 4, wherein the matrix comprises a plurality of multiparticulates.

6. The dosage form of claim 5, wherein the multiparticulates are compressed into a tablet.

7. The dosage form of claim 5, wherein the multiparticulates are disposed in a pharmaceutically acceptable capsule.

8. The dosage form of claim 1, comprising a bitartrate salt of the hydrocodone.

9. The dosage form of claim 1, which provides a C.sub.24/C.sub.max hydrocodone ratio of 0.60 to 0.70.

10. The dosage form of claim 1, which provides a dissolution release rate in-vitro of the hydrocodone or the pharmaceutically acceptable salt thereof, when measured by the USP Basket method at 100 rpm in 700 ml aqueous buffer at a pH of 1.2 at 37.degree. C., such that at least 10% to about 45% by weight hydrocodone or salt thereof is released at 1 hour.

11. The dosage form of claim 1, which provides a time to maximum plasma concentration (T.sub.max) of hydrocodone at about 4 to about 14 hours after oral administration of the dosage form.

12. The dosage form of claim 1, which provides a time to maximum plasma concentration (T.sub.max) of hydrocodone at about 6 to about 12 hours after oral administration of the dosage form.

13. The dosage form of claim 1, which provides a C.sub.max of hydrocodone which is less than 60% of the C.sub.max of an equivalent dose of an immediate release hydrocodone reference formulation.

14. The dosage form of claim 1, wherein said C.sub.24/C.sub.max hydrocodone ratio is obtained from a population of patients.

15. The dosage form of claim 1, wherein the non-opioid drug is selected from the group consisting of a non-steroidal anti-inflammatory agent, an NMDA receptor antagonist, acetaminophen, aspirin, a neuro-active steroid, a non-opioid analgesic, their mixtures and pharmaceutically acceptable salts thereof.

16. The dosage form of claim 15, wherein the non-opioid analgesic is acetaminophen.

17. The dosage form of claim 1, further comprising additional hydrocodone or the salt in an immediate release form.

18. The dosage form of claim 17, wherein the immediate release form is coated onto a substrate comprising the compressed granulation.

19. A solid oral controlled-release dosage form comprising a compressed granulation in the form of a controlled release matrix, the compressed granulation comprising hydrocodone or a pharmaceutically acceptable salt thereof, acetaminophen or a pharmaceutically acceptable salt thereof and a controlled release material comprising a methacrylic acid polymer or copolymer; wherein the hydrocodone and acetaminophen are the only active agents in the dosage form, the dosage form provides an in-vitro release rate of the hydrocodone or the pharmaceutically acceptable salt thereof, when measured by the USP Basket Method at 100 rpm in 700 ml Simulated Gastric Fluid (SGF) at 37.degree. C. for 1 hour and thereafter switching to 900 ml with Phosphate Buffer to a pH of 7.5 at 37.degree. C., such that at least 20% by weight hydrocodone or salt thereof is released at 4 hours, from about 20% to about 65% by weight hydrocodone or salt thereof is released at 8 hours, from about 45% to about 85% by weight hydrocodone or salt thereof is released at 12 hours, and at least 80% by weight hydrocodone or salt thereof is released at 24 hours, and after a first administration to a human patient, provides a C.sub.24/C.sub.max hydrocodone ratio of 0.55 to about 0.85, a W.sub.50 of hydrocodone of between 4 and 22 hours and a therapeutic effect for about 24 hours.

20. The dosage form of claim 19, comprising additional hydrocodone or the salt thereof in an immediate release form.

21. The dosage form of claim 20, wherein the immediate release form is coated onto a substrate comprising the compressed granulation.

22. The dosage form of claim 19, wherein the W.sub.50 of the hydrocodone is at least 12 hours.

23. The dosage form of claim 19, wherein the W.sub.50 of the hydrocodone is at least 18 hours.

24. The dosage form of claim 19, wherein the dosage form comprises from about 5 to about 60 mg of the hydrocodone.

25. The dosage form of claim 24, wherein the dosage form comprises 30 mg of the hydrocodone.

26. The dosage form of claim 19, which provides a dissolution release rate in-vitro of the hydrocodone, when measured by the USP Basket method at 100 rpm in 700 ml aqueous buffer at a pH of 1.2 at 37.degree. C., such that at least 10% to about 45% by weight hydrocodone or salt thereof is released at 1 hour.

27. The dosage form of claim 19, comprising a bitartrate salt of the hydrocodone.

28. The dosage form of claim 1, which provides a W.sub.50 of hydrocodone of at least 12 hours.

29. The dosage form of claim 1, which provides a W.sub.50 of hydrocodone of at least 18 hours.

30. The dosage form of claim 1, which provides a W.sub.50 of hydrocodone of at least 4 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc